KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
US6608182B1
(en)
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
EP0751992B1
(en)
|
1994-03-08 |
2005-11-09 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7153827B1
(en)
|
1994-03-08 |
2006-12-26 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 and methods of use
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7109308B1
(en)
|
1994-03-08 |
2006-09-19 |
Human Genome Sciences, Inc. |
Antibodies to human vascular endothelial growth factor 2
|
US7186688B1
(en)
|
1994-03-08 |
2007-03-06 |
Human Genome Sciences, Inc. |
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
|
DK0859841T3
(da)
*
|
1995-08-18 |
2002-09-09 |
Morphosys Ag |
Protein/(poly)peptidbiblioteker
|
EP0866805A1
(en)
|
1995-12-12 |
1998-09-30 |
Karolinska Innovations AB |
PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
|
US6141769A
(en)
|
1996-05-16 |
2000-10-31 |
Resilience Corporation |
Triple modular redundant computer system and associated method
|
US6696251B1
(en)
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US6300065B1
(en)
*
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
GB9701425D0
(en)
*
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
JP2010213725A
(ja)
*
|
1998-01-20 |
2010-09-30 |
Univ Illinois |
タンパク質の酵母細胞表面ディスプレイおよびその使用
|
CA2323787A1
(en)
*
|
1998-03-13 |
1999-09-16 |
Wayne Marasco |
Humanized antibody and uses thereof
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
EP0953639A1
(en)
*
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
EP1131428A2
(en)
*
|
1998-11-19 |
2001-09-12 |
Incyte Pharmaceuticals, Inc. |
Immunoglobulin superfamily proteins
|
US6787638B1
(en)
*
|
1998-12-02 |
2004-09-07 |
Applied Molecular Evolution, Inc. |
Tumor specific human monoclonal antibodies and methods of use
|
JP5550799B2
(ja)
|
1999-01-15 |
2014-07-16 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
US7060670B1
(en)
|
1999-05-05 |
2006-06-13 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
CZ300710B6
(cs)
|
1999-06-01 |
2009-07-22 |
Biogen Idec Ma Inc. |
Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
|
US20090233806A1
(en)
*
|
1999-07-06 |
2009-09-17 |
Carr Francis J |
Protein isolation and analysis
|
WO2001005950A2
(en)
|
1999-07-20 |
2001-01-25 |
Morphosys Ag |
Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
|
US7351540B1
(en)
*
|
2000-03-17 |
2008-04-01 |
Merck Patent Gmbh |
Protein isolation and analysis
|
JP2001275682A
(ja)
*
|
2000-03-31 |
2001-10-09 |
Kankyo Meneki Gijutsu Kenkyusho:Kk |
抗マラチオンモノクローナル抗体をコードする遺伝子
|
GB0008419D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Bioinvent Int Ab |
A method for invitro molecular evolution of antibody function
|
WO2001077342A1
(en)
|
2000-04-11 |
2001-10-18 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
US20040029113A1
(en)
|
2000-04-17 |
2004-02-12 |
Ladner Robert C. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
AU2005200250B2
(en)
*
|
2000-05-08 |
2007-10-25 |
Celldex Therapeutics, Inc. |
Human monoclonal antibodies to dendritic cells
|
US7521047B2
(en)
|
2000-05-12 |
2009-04-21 |
Gpc Biotech Ag |
Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
|
US20040019187A1
(en)
*
|
2000-05-12 |
2004-01-29 |
Zoltan Nagy |
Immunomodulatory human mhc class II antigens-binding polypeptides
|
EP1156062A1
(en)
*
|
2000-05-12 |
2001-11-21 |
GPC Biotech AG |
Immunomodulatory human MHC class II antigen-binding peptides/proteins
|
ATE420958T1
(de)
|
2000-06-29 |
2009-01-15 |
Abbott Lab |
Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
US7452964B2
(en)
*
|
2001-09-07 |
2008-11-18 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of targeting peptides against placenta and adipose tissues
|
US7420030B2
(en)
|
2000-09-08 |
2008-09-02 |
The Board Of Regents Of The University Of Texas System |
Aminopeptidase A (APA) targeting peptides for the treatment of cancer
|
US20040170955A1
(en)
*
|
2000-09-08 |
2004-09-02 |
Wadih Arap |
Human and mouse targeting peptides identified by phage display
|
US20050074747A1
(en)
*
|
2000-09-08 |
2005-04-07 |
Wadih Arap |
Biopanning and rapid analysis of selective interactive ligands (brasil)
|
US7051028B2
(en)
*
|
2000-11-15 |
2006-05-23 |
Ndsu-Research Foundation |
Concurrency control in high performance database systems
|
US7858559B2
(en)
|
2000-11-17 |
2010-12-28 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
WO2002059280A2
(en)
|
2000-12-08 |
2002-08-01 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
AU2011223997B2
(en)
*
|
2000-12-18 |
2013-09-19 |
Dyax Corp. |
Focused Libraries of Genetic Packages
|
CA2784251A1
(en)
|
2000-12-18 |
2002-08-08 |
Dyax Corp. |
Focused libraries of genetic packages
|
MY138286A
(en)
|
2001-04-13 |
2009-05-29 |
Biogen Idec Inc |
Antibodies to vla-1
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
US7402312B2
(en)
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
EP1390741B1
(en)
*
|
2001-04-17 |
2012-10-31 |
Abmaxis, Inc. |
Structure-based construction of human antibody library
|
US7117096B2
(en)
*
|
2001-04-17 |
2006-10-03 |
Abmaxis, Inc. |
Structure-based selection and affinity maturation of antibody library
|
US20040010376A1
(en)
*
|
2001-04-17 |
2004-01-15 |
Peizhi Luo |
Generation and selection of protein library in silico
|
WO2002102854A2
(en)
|
2001-06-20 |
2002-12-27 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
GB0115841D0
(en)
|
2001-06-28 |
2001-08-22 |
Medical Res Council |
Ligand
|
CA2454357A1
(en)
*
|
2001-07-18 |
2003-01-30 |
Wadih Arap |
An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
WO2003014960A2
(en)
|
2001-08-03 |
2003-02-20 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
US20040048243A1
(en)
*
|
2001-09-07 |
2004-03-11 |
Wadih Arap |
Methods and compositions for in vitro targeting
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
WO2003035679A2
(en)
|
2001-10-25 |
2003-05-01 |
Medical Research Council |
Molecules
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
JP2005517388A
(ja)
*
|
2001-11-19 |
2005-06-16 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
腫瘍特異的モノクローナル抗体
|
US7115716B2
(en)
*
|
2001-11-19 |
2006-10-03 |
Eli Lilly And Company |
Tumor specific monoclonal antibodies
|
EP2298817A1
(en)
|
2001-12-03 |
2011-03-23 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
AU2003217912A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
MXPA04008870A
(es)
*
|
2002-03-13 |
2005-06-17 |
Biogen Idec Inc |
Anticuerpos anti-avb6.
|
IL164352A0
(en)
|
2002-04-09 |
2005-12-18 |
Biogen Idec Inc |
Methods for treating tweak-related conditions
|
NZ536412A
(en)
|
2002-05-22 |
2008-10-31 |
Esbatech Ag |
Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
|
AU2003239544A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Tularik Inc. |
Amplification and overexpression of oncogenes
|
US20030232387A1
(en)
*
|
2002-06-14 |
2003-12-18 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind alphaE integrin
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
WO2004015063A2
(en)
*
|
2002-08-07 |
2004-02-19 |
Tularik Inc. |
Amplification and overexpression of oncogenes
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
GB0226729D0
(en)
*
|
2002-11-15 |
2002-12-24 |
Medical Res Council |
Intracellular antibodies
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
AU2004239065B2
(en)
|
2003-05-14 |
2008-05-15 |
Domantis Limited |
A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
US20040248189A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Grzegorz Bulaj |
Method of making a library of phylogenetically related sequences
|
NZ544486A
(en)
|
2003-06-13 |
2009-04-30 |
Biogen Idec Inc |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
US20050026194A1
(en)
*
|
2003-06-20 |
2005-02-03 |
Tularik Inc. |
Gene amplification and overexpression in cancer
|
HN2004000285A
(es)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
DE10346627A1
(de)
*
|
2003-10-08 |
2005-05-19 |
Weiss, Stefan, PD Dr. |
Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
|
ES2405848T3
(es)
*
|
2003-12-23 |
2013-06-04 |
Biokit S.A. |
Composiciones y métodos para detección de infección patógena
|
DK1720907T3
(en)
|
2004-02-06 |
2015-06-15 |
Morphosys Ag |
Human anti-CD38 antibodies as well as applications therefor
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
WO2005087812A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for vegf/pdgf family of growth factors
|
US7311906B2
(en)
|
2004-04-30 |
2007-12-25 |
Brigham Young University |
Anti-viral activity of an anti-thymidine kinase monoclonal antibody
|
CA2810292C
(en)
|
2004-05-14 |
2015-09-29 |
Euroscreen S.A. |
Ligand for g-protein coupled receptor fprl2 and uses thereof
|
US8551486B2
(en)
|
2004-05-21 |
2013-10-08 |
Savoy Pharmaceuticals, Inc. |
Monoclonal antibodies to human thymidine kinase to treat cancer
|
US7837998B2
(en)
|
2004-05-21 |
2010-11-23 |
Nathaniel Lallatin |
Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
WO2006004663A2
(en)
*
|
2004-06-25 |
2006-01-12 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
EP2322554A1
(en)
|
2004-06-30 |
2011-05-18 |
Domantis Limited |
Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
|
MX2007000103A
(es)
*
|
2004-07-06 |
2007-05-11 |
Bioren Inc |
Bibliotecas de anticuerpos universales.
|
EP2399936A3
(en)
|
2004-07-26 |
2012-02-22 |
Biogen Idec MA Inc. |
Anti-CD154 antibodies
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
|
DK3540062T3
(da)
|
2004-11-16 |
2021-06-28 |
Humanigen Inc |
Immunoglobulin-variabel region kassetteudskiftning
|
EP2769990A3
(en)
|
2004-12-02 |
2015-02-25 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
|
TW200635607A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
CA2597945C
(en)
|
2005-02-17 |
2016-07-12 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
EP2481424A1
(en)
|
2005-03-19 |
2012-08-01 |
Medical Research Council |
Improvements in or relating to treatment and prevention of hepatitis C viral infections
|
AU2006244014B2
(en)
|
2005-05-10 |
2011-03-17 |
Biogen Ma Inc. |
Treating and evaluating inflammatory disorders
|
EP2559690B1
(en)
|
2005-05-10 |
2016-03-30 |
Incyte Holdings Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
PT3620171T
(pt)
|
2005-05-18 |
2022-06-30 |
Morphosys Ag |
Anticorpos anti-gm-csf e suas utilizações
|
US20090123950A1
(en)
|
2005-05-24 |
2009-05-14 |
Morphosys Ag |
Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
|
CA2609600C
(en)
|
2005-05-27 |
2016-11-08 |
Biogen Idec Ma Inc. |
Tweak binding antibodies
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
CA3018525C
(en)
*
|
2005-07-01 |
2023-08-01 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
CN103554259B
(zh)
|
2005-10-12 |
2016-05-18 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
AR058140A1
(es)
*
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
ZA200804082B
(en)
|
2005-11-07 |
2010-02-24 |
Scripps Research Inst |
Compositions and methods for controlling tissue factor signaling specificity
|
BRPI0520677A2
(pt)
|
2005-11-09 |
2009-05-19 |
Bayer Schering Pharma Ag |
identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
PL2289909T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
|
WO2007063311A2
(en)
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Competitive domain antibody formats that bind interleukin 1 receptor type 1
|
AU2006321364B2
(en)
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
RS52004B
(en)
|
2005-12-12 |
2012-04-30 |
F. Hoffmann-La Roche Ag |
ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
|
JP5405831B2
(ja)
|
2005-12-20 |
2014-02-05 |
モルフォシス アーゲー |
H−cdr3領域の新規集合体およびその使用
|
ES2709672T3
(es)
|
2006-01-12 |
2019-04-17 |
Alexion Pharma Inc |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
US8541177B2
(en)
|
2006-01-13 |
2013-09-24 |
A Chan Holding B.V. |
Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
SI2671954T1
(sl)
|
2006-01-20 |
2018-11-30 |
Cell Signaling Technology, Inc. |
Translokacija in mutantna ROS kinaza v človeškem ne-drobnoceličnem karcinomu pljuč
|
AU2007211829C9
(en)
|
2006-02-01 |
2013-07-11 |
Cephalon Australia Pty Ltd |
Domain antibody construct
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
WO2007109243A2
(en)
*
|
2006-03-20 |
2007-09-27 |
Duramed Pharmaceuticals, Inc. |
Methods for comparing the immunogenicity of products and uses thereof
|
EP2010567A2
(en)
|
2006-04-07 |
2009-01-07 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
WO2007117657A2
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
PL2450437T3
(pl)
|
2006-04-14 |
2017-12-29 |
Cell Signaling Technology Inc |
Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
CN101443361B
(zh)
|
2006-04-28 |
2015-08-19 |
德勒尼克斯治疗股份公司 |
与受体酪氨酸激酶alk的胞外域结合的抗体
|
EP1918302A3
(en)
*
|
2006-05-18 |
2009-11-18 |
AvantGen, Inc. |
Methods for the identification and the isolation of epitope specific antibodies
|
AU2007267579B2
(en)
*
|
2006-05-25 |
2013-05-30 |
Biogen Ma Inc. |
Methods of treating stroke
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
AU2007272995B2
(en)
|
2006-07-10 |
2013-02-07 |
Biogen Idec Ma Inc. |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
AU2007302626B2
(en)
|
2006-09-28 |
2013-09-26 |
The Macfarlane Burnet Institute For Medical Research And Public Health Limited |
A method of diagnosis and kit therefor
|
CA2664681C
(en)
|
2006-10-02 |
2020-07-07 |
Sea Lane Biotechnologies, Llc |
Design and construction of diverse synthetic peptide and polypeptide libraries
|
WO2008045563A2
(en)
*
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
CA2666317C
(en)
*
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
EP2089029B1
(en)
|
2006-11-10 |
2012-10-03 |
Massachusetts Institute of Technology |
Pak inhibitors for use in treating neurodevelopmental disorders
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8324350B2
(en)
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
EP2126105A4
(en)
*
|
2007-02-20 |
2010-11-03 |
Anaptysbio Inc |
SOMATIC HYPERPERMUTATION SYSTEMS
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
JP2010521670A
(ja)
|
2007-03-12 |
2010-06-24 |
ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド |
Fanciおよびfanciを調整する薬剤の予後での、診断での、および癌治療での使用
|
AU2008232409C1
(en)
|
2007-03-22 |
2013-12-05 |
Biogen Ma Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
CN111253484A
(zh)
|
2007-06-25 |
2020-06-09 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
CA2694121C
(en)
|
2007-07-25 |
2016-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
AU2008292352B2
(en)
|
2007-08-30 |
2012-03-08 |
Daiichi Sankyo Company, Limited |
Anti-EPHA2 antibody
|
US8691730B2
(en)
|
2007-09-14 |
2014-04-08 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
JP5769968B2
(ja)
|
2007-10-18 |
2015-08-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト非小細胞肺癌における転座および変異rosキナーゼ
|
JP2011504236A
(ja)
*
|
2007-11-20 |
2011-02-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
ジアセチレンを含むポリマーセンサーを用いる細菌試料の分析方法
|
JP5608091B2
(ja)
*
|
2007-11-26 |
2014-10-15 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
抗メソセリン抗体およびその使用
|
EP2222709B1
(en)
|
2007-11-30 |
2016-11-23 |
Glaxo Group Limited |
Antigen-binding constructs
|
EP2080770A1
(en)
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
AU2009240481B2
(en)
|
2008-04-24 |
2015-07-30 |
Takeda Pharmaceutical Company Limited |
Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
|
EP2116618A1
(en)
|
2008-05-09 |
2009-11-11 |
Agency for Science, Technology And Research |
Diagnosis and treatment of Kawasaki disease
|
AU2009269095B2
(en)
|
2008-07-08 |
2016-05-19 |
Oncomed Pharmaceuticals, Inc. |
Notch-binding agents and antagonists and methods of use thereof
|
RS53688B9
(sr)
|
2008-07-08 |
2020-01-31 |
Incyte Holdings Corp |
1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
|
NZ590343A
(en)
|
2008-07-18 |
2012-10-26 |
Bristol Myers Squibb Co |
Compositions monovalent for cd28 binding and methods of use
|
CA2731686C
(en)
*
|
2008-07-25 |
2020-04-07 |
Institute For Research In Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
CN102176914B
(zh)
|
2008-08-08 |
2014-12-17 |
新加坡科技研究局 |
用于诊断和治疗癌症的vhz
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-il-12/il-23 항체
|
CA2739357A1
(en)
|
2008-09-23 |
2010-04-08 |
Wyeth Llc |
Methods for predicting production of activating signals by cross-linked binding proteins
|
CA2740138C
(en)
*
|
2008-10-22 |
2017-01-10 |
Institute For Research In Biomedicine |
Methods for producing antibodies from plasma cells
|
KR20110079693A
(ko)
|
2008-10-29 |
2011-07-07 |
와이어쓰 엘엘씨 |
단일 도메인 항원 결합 분자의 정제 방법
|
AU2009333791B2
(en)
|
2008-10-29 |
2013-04-04 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
JP5882058B2
(ja)
|
2008-11-07 |
2016-03-09 |
ファブラス エルエルシー |
組合せ抗体ライブラリー及びその使用
|
NZ592786A
(en)
|
2008-11-10 |
2013-02-22 |
Alexion Pharma Inc |
Methods and compositions for treating complement-associated disorders using eculizumab
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
WO2010063818A2
(en)
|
2008-12-05 |
2010-06-10 |
Glaxo Group Limited |
Methods for selecting protease resistant polypeptides
|
BRPI0918356B1
(pt)
|
2008-12-22 |
2022-03-08 |
The University Of Melbourne |
Uso de um antagonista de gm-cfs
|
ES2685895T3
(es)
|
2008-12-22 |
2018-10-15 |
The University Of Melbourne |
Tratamiento del dolor
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗-mst1r抗體及其用途
|
DK2881402T3
(en)
|
2009-02-12 |
2017-08-28 |
Cell Signaling Technology Inc |
Mutant ROS expression in human liver cancer
|
CN102239181A
(zh)
|
2009-02-24 |
2011-11-09 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
用于鉴定细胞表面抗原的免疫结合剂的方法
|
EP2401297A1
(en)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigen-binding constructs
|
EP2401298A1
(en)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigen-binding constructs
|
JP2012518400A
(ja)
|
2009-02-24 |
2012-08-16 |
グラクソ グループ リミテッド |
多価および/または複数特異的rankl結合性構築物
|
WO2010102982A1
(en)
*
|
2009-03-10 |
2010-09-16 |
Dsm Ip Assets B.V. |
Method for improving the yield of a polypeptide
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
UA112282C2
(uk)
|
2009-04-29 |
2016-08-25 |
Янссен Байотек, Інк. |
Антагоніст толл-подібного рецептора 3
|
EP2799453B1
(en)
|
2009-04-29 |
2019-04-03 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
ERG2 monoclonal antibodies and their therapeutic use
|
US8921281B2
(en)
|
2009-05-20 |
2014-12-30 |
Novimmune S.A. |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
CA2758356C
(en)
|
2009-05-29 |
2016-07-26 |
Morphosys Ag |
A collection of vh and vl pairs having favourable biophysical properties and methods for its use
|
SG176947A1
(en)
|
2009-07-03 |
2012-01-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
SG177583A1
(en)
|
2009-07-09 |
2012-02-28 |
Hoffmann La Roche |
In vivo tumor vasculature imaging
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
JP2013504602A
(ja)
*
|
2009-09-14 |
2013-02-07 |
ダイアックス コーポレーション |
新しく設計したhccdr3を含む遺伝子パッケージライブラリー
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
JP6007420B2
(ja)
|
2009-11-04 |
2016-10-12 |
ファブラス エルエルシー |
親和性成熟に基づく抗体最適化方法
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
MX2012006593A
(es)
|
2009-12-09 |
2012-06-28 |
Bayer Pharma AG |
Anticuerpos anti-c4.4a y usos de los mismos.
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
JP2013514788A
(ja)
|
2009-12-23 |
2013-05-02 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法2
|
WO2011082345A2
(en)
|
2009-12-30 |
2011-07-07 |
Brigham Young University |
Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
|
CA2786692A1
(en)
|
2010-01-11 |
2011-07-14 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
EP2523682B1
(en)
|
2010-01-13 |
2015-12-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
EP2354159A1
(en)
|
2010-02-05 |
2011-08-10 |
RWTH Aachen |
CCL17 inhibitors for use in T helper cell-driven diseases
|
WO2011100566A2
(en)
|
2010-02-12 |
2011-08-18 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
EP2536760A4
(en)
|
2010-02-17 |
2013-10-16 |
Univ Johns Hopkins |
NEW PHOSPHORYLATION OF CARDIAC TROPONIN I AS A MONITOR OF CARDIAC INJURY
|
DK2538976T3
(en)
|
2010-02-24 |
2017-02-27 |
Immunogen Inc |
IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
PT2544719T
(pt)
|
2010-03-12 |
2019-10-17 |
Debiopharm Int Sa |
Moléculas de ligação a cd37 e imunoconjugados das mesmas
|
EP2558494B1
(en)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン.ヴェー. |
修飾された単一ドメイン抗原結合分子及びその使用
|
CN103282560B
(zh)
|
2010-07-16 |
2016-08-03 |
阿迪马布有限责任公司 |
抗体文库
|
NZ604415A
(en)
|
2010-07-20 |
2014-10-31 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
RU2013113638A
(ru)
|
2010-08-27 |
2014-10-10 |
Стем Сентркс, Инк. |
МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
ES2719624T3
(es)
|
2010-09-23 |
2019-07-11 |
Prec Biologics Inc |
Peptidomiméticos de cáncer de colon y de páncreas
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
JP6253986B2
(ja)
|
2010-11-19 |
2017-12-27 |
モルフォシス・アーゲー |
コレクション及びその使用方法
|
SG190362A1
(en)
|
2010-11-24 |
2013-06-28 |
Glaxo Group Ltd |
Multispecific antigen binding proteins targeting hgf
|
RU2592672C9
(ru)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Новые модуляторы и способы их применения
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
US20140050743A1
(en)
|
2011-01-19 |
2014-02-20 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
CA3042620A1
(en)
|
2011-02-02 |
2012-11-29 |
Emory University |
Antagonism of the vip signaling pathway
|
US9447187B2
(en)
|
2011-02-03 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
KR20140018299A
(ko)
|
2011-03-30 |
2014-02-12 |
아블린쓰 엔.브이. |
Tnf-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
|
US20140010886A1
(en)
|
2011-04-07 |
2014-01-09 |
Georgia Tech Research Corporation |
Compositions comprising saccharide binding moieties and methods for targeted therapy
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
EP2699597B1
(en)
|
2011-04-21 |
2016-06-01 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
JP2014515753A
(ja)
|
2011-04-21 |
2014-07-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
新規な結合剤−薬物複合体(adc)およびそれらの使用
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US20140213459A1
(en)
|
2011-05-27 |
2014-07-31 |
Roland Beckmann |
Antibodies with improved folding stability
|
PT2726510T
(pt)
|
2011-05-27 |
2023-05-03 |
Hoffmann La Roche |
Direcionamento duplo
|
US20140255405A1
(en)
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
CA2838246C
(en)
|
2011-06-13 |
2018-07-10 |
Csl Limited |
Antibodies against g-csfr and uses thereof
|
ES2552427T3
(es)
|
2011-06-16 |
2015-11-27 |
Universitätsklinikum Freiburg |
Composición farmacéutica con anticuerpos contra catalasa y superóxido dismutasa
|
EP3401329A1
(en)
|
2011-07-15 |
2018-11-14 |
OncoMed Pharmaceuticals, Inc. |
Rspo binding agents and uses thereof
|
EP3812397A1
(en)
|
2011-07-18 |
2021-04-28 |
Institute for Research in Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
US9243066B2
(en)
|
2011-07-18 |
2016-01-26 |
University Of Melbourne |
Use of M-CSF antibodies in the treatment of osteoarthritis or pain
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
BR112014005786A2
(pt)
|
2011-09-12 |
2017-03-28 |
Janssen Biotech Inc |
antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares
|
HRP20230078T1
(hr)
|
2011-09-23 |
2023-05-12 |
Mereo Biopharma 5, Inc. |
Sredstva za vezivanje vegf/dll4 i njihova uporaba
|
JP2014533929A
(ja)
|
2011-09-23 |
2014-12-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
5t4およびcd3に対する二重特異的結合性分子
|
AU2012315474B2
(en)
|
2011-09-30 |
2017-10-26 |
Teva Pharmaceuticals Australia Pty Ltd. |
Antibodies against TL1a and uses thereof
|
DK2764140T3
(en)
|
2011-10-07 |
2017-12-04 |
Bicyclerd Ltd |
MODULATION OF STRUCTURED POLYPEPTIME SPECIFICITY
|
RS57209B1
(sr)
|
2011-10-19 |
2018-07-31 |
Morphosys Ag |
Antagonisti il17c za lečenje zapaljenskih poremećaja
|
JP6184965B2
(ja)
|
2011-10-28 |
2017-08-23 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
ポリペプチド構築物およびその使用
|
US9265817B2
(en)
|
2011-10-28 |
2016-02-23 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
SG11201402536PA
(en)
|
2011-11-23 |
2014-06-27 |
Medimmune Llc |
Binding molecules specific for her3 and uses thereof
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
BR112014014763A8
(pt)
|
2011-12-14 |
2017-07-04 |
Seattle Genetics Inc |
novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos
|
HUE039611T2
(hu)
|
2012-01-27 |
2019-01-28 |
Abbvie Deutschland |
Készítmények és eljárások axondegenerációval járó betegségek diagnózisára és kezelésére
|
ES2732243T3
(es)
|
2012-02-16 |
2019-11-21 |
Santarus Inc |
Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
|
ES2645272T3
(es)
|
2012-02-24 |
2017-12-04 |
Abbvie Stemcentrx Llc |
Moduladores de DLL3 y procedimientos de utilización
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
US9708388B2
(en)
|
2012-04-11 |
2017-07-18 |
Hoffmann-La Roche Inc. |
Antibody light chains
|
HUE037856T2
(hu)
|
2012-04-18 |
2018-09-28 |
Cell Signaling Technology Inc |
EGFR és ROS1 rákban
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
US9783614B2
(en)
|
2012-05-10 |
2017-10-10 |
Bayer Pharma Aktiengesellschaft |
Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
WO2014003830A1
(en)
|
2012-06-25 |
2014-01-03 |
Emory University |
Particle-nucleic acid conjugates and therapeutic uses related thereto
|
IL299620A
(en)
|
2012-08-31 |
2023-03-01 |
Immunogen Inc |
Tests and diagnostic kits for the detection of folate receptor 1
|
US20150284472A1
(en)
|
2012-11-05 |
2015-10-08 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
HUE047874T2
(hu)
|
2012-12-10 |
2020-05-28 |
Biogen Ma Inc |
Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
KR102204127B1
(ko)
|
2013-02-01 |
2021-01-20 |
키라 바이오테크 피티와이 리미티드 |
항-cd83 항체 및 이의 용도
|
CN104995211B
(zh)
|
2013-02-07 |
2019-09-13 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
PT2958944T
(pt)
|
2013-02-22 |
2019-06-27 |
Medimmune Ltd |
Conjugados de anticorpos anti-dll3 e pbd e suas utilizações
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
CN112870368A
(zh)
|
2013-03-27 |
2021-06-01 |
西达-赛奈医疗中心 |
通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
|
GB201306623D0
(en)
|
2013-04-11 |
2013-05-29 |
Bicycle Therapeutics Ltd |
Modulation of structured polypeptide specificity
|
KR102094022B1
(ko)
|
2013-04-29 |
2020-03-30 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-cd38 항체 및 감쇠 인터페론 알파-2b와의 융합체
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
AU2014280174A1
(en)
|
2013-06-14 |
2015-12-03 |
Bayer Pharma Aktiengesellschaft |
Anti-TWEAKR antibodies and uses thereof
|
US10316083B2
(en)
|
2013-07-19 |
2019-06-11 |
Cedars-Sinai Medical Center |
Signature of TL1A (TNFSF15) signaling pathway
|
EP4282975A3
(en)
|
2013-07-23 |
2024-02-28 |
Biocon Limited |
Methods for controlling fucosylation levels in proteins
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
AU2014312310A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Novel SEZ6 modulators and methods of use
|
SG10201907501QA
(en)
|
2013-08-30 |
2019-10-30 |
Immunogen Inc |
Antibodies and assays for detection of folate receptor 1
|
EP4215209A1
(en)
|
2013-09-02 |
2023-07-26 |
The University of Melbourne |
A method of treatment
|
CN118005782A
(zh)
|
2013-10-02 |
2024-05-10 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
CN106164093A
(zh)
|
2013-10-08 |
2016-11-23 |
伊缪诺金公司 |
抗folr1免疫偶联物给药方案
|
ES2711882T3
(es)
|
2013-11-28 |
2019-05-08 |
B Creative Sweden Ab |
Método de tratamiento de la nefropatía diabética
|
US9309314B2
(en)
|
2013-12-03 |
2016-04-12 |
Agency For Science, Technology And Research (A*Star) |
Polypeptides, nucleic acids and uses thereof
|
JP2017502002A
(ja)
|
2013-12-09 |
2017-01-19 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌剤の食細胞送達用組成物及び方法
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
WO2015089585A1
(en)
|
2013-12-18 |
2015-06-25 |
Csl Limited |
Method of treating wounds
|
EP3086814B1
(de)
|
2013-12-23 |
2020-06-24 |
Bayer Pharma Aktiengesellschaft |
Binder-konjugate (adcs) mit ksp-inhibitoren
|
WO2015108719A1
(en)
|
2014-01-14 |
2015-07-23 |
The Medical College Of Wisconsin, Inc. |
Targeting clptm1l for treatment and prevention of cancer
|
CR20160437A
(es)
|
2014-02-21 |
2017-02-20 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
DK3126384T3
(da)
|
2014-04-01 |
2021-01-18 |
Adimab Llc |
Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
|
CN111560071B
(zh)
|
2014-04-08 |
2023-09-05 |
波士顿制药有限公司 |
对il-21具有特异性的结合分子及其用途
|
US10160812B2
(en)
|
2014-04-11 |
2018-12-25 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
JP2017518737A
(ja)
|
2014-04-21 |
2017-07-13 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
SYK標的治療薬のための抗pSYK抗体分子及びその使用
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
US9903868B2
(en)
|
2014-05-16 |
2018-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for the detection and quantitation of biomarkers
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
CN106573154B
(zh)
|
2014-07-15 |
2021-06-15 |
免疫医疗有限责任公司 |
中和抗乙型流感抗体及其用途
|
AU2015295242B2
(en)
|
2014-07-31 |
2020-10-22 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
MX2017001401A
(es)
|
2014-07-31 |
2017-08-07 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
WO2016061617A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
MX2017005481A
(es)
|
2014-10-29 |
2017-10-26 |
Teva Pharmaceuticals Australia Pty Ltd |
Variantes de interferon a2b.
|
DK3218406T3
(da)
|
2014-11-10 |
2021-06-21 |
Medimmune Ltd |
Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
KR102657306B1
(ko)
|
2014-12-08 |
2024-04-12 |
버그 엘엘씨 |
전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
|
JP6743015B2
(ja)
|
2014-12-15 |
2020-08-19 |
バイエル ファーマ アクチエンゲゼルシャフト |
Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
EP3253801B1
(de)
|
2015-02-02 |
2020-03-04 |
Georg Bauer |
Einzeldomänen-vhh-fragmente, die an katalase bzw. superoxiddismutase binden und diese inhibieren zur behandlung von tumorerkrankungen
|
JP2018507254A
(ja)
|
2015-02-02 |
2018-03-15 |
アイツー ファーマシューティカルズ, インコーポレーテッド |
抗代替軽鎖抗体
|
RU2739163C2
(ru)
|
2015-03-23 |
2020-12-21 |
Байер Фарма Акциенгезельшафт |
Анти-сеасам6 антитела и их применения
|
US11136401B2
(en)
|
2015-03-27 |
2021-10-05 |
University Of Southern California |
Car t-cell therapy directed to LHR for the treatment of solid tumors
|
MY190209A
(en)
|
2015-03-31 |
2022-04-05 |
Medimmune Ltd |
A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
|
CA2982131A1
(en)
|
2015-04-10 |
2016-10-13 |
Adimab, Llc |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
EA201792193A1
(ru)
|
2015-04-17 |
2018-05-31 |
Эмджен Рисерч (Мьюник) Гмбх |
Конструкции биспецифического антитела для cdh3 и cd3
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
US10900975B2
(en)
|
2015-05-12 |
2021-01-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Systems and methods of epitope binning and antibody profiling
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
PT3303384T
(pt)
|
2015-06-01 |
2021-10-14 |
Medimmune Llc |
Moléculas de ligação neutralizantes anti-influenza e suas utilizações
|
EP3302559B1
(en)
|
2015-06-04 |
2022-01-12 |
University of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
CN114917361A
(zh)
|
2015-06-22 |
2022-08-19 |
拜耳医药股份有限公司 |
具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
|
JP6905941B2
(ja)
|
2015-06-23 |
2021-07-21 |
バイエル ファーマ アクチエンゲゼルシャフト |
キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体
|
JP2018525334A
(ja)
|
2015-06-23 |
2018-09-06 |
バイエル ファーマ アクチエンゲゼルシャフト |
キネシンスピンドルタンパク質(ksp)阻害剤の抗tweakr抗体との抗体薬物複合体
|
BR112017024610A2
(pt)
|
2015-06-24 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
anticorpos para receptor antitransferrina com afinidade especificada
|
EP3313884B9
(en)
|
2015-06-29 |
2021-05-19 |
ImmunoGen, Inc. |
Anti-cd123 antibodies and conjugates and derivatives thereof
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
AU2016323968B2
(en)
|
2015-09-17 |
2023-07-06 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-FOLR1 immunoconjugates
|
JP7054924B2
(ja)
|
2015-09-23 |
2022-04-15 |
サイトイミューン セラピューティクス, インコーポレイテッド |
免疫療法のためのflt3指向car細胞
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43023A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
|
WO2017060289A1
(en)
|
2015-10-05 |
2017-04-13 |
Morphosys Ag |
Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
ES2959663T3
(es)
|
2015-11-10 |
2024-02-27 |
Medimmune Llc |
Moléculas de unión específicas para ASCT2 y usos de las mismas
|
CN108697789A
(zh)
|
2016-01-13 |
2018-10-23 |
免疫医疗有限责任公司 |
治疗甲型流感的方法
|
JP6959011B2
(ja)
|
2016-02-03 |
2021-11-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
SI3411404T1
(sl)
|
2016-02-03 |
2023-01-31 |
Amgen Research (Munich) Gmbh |
Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico
|
CA3017197A1
(en)
|
2016-03-10 |
2017-09-14 |
Viela Bio, Inc. |
Ilt7 binding molecules and methods of using the same
|
KR20230152153A
(ko)
|
2016-03-10 |
2023-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈 타입 2 수용체 결합 단백질 및 이의 용도
|
EP4302782A3
(en)
|
2016-03-15 |
2024-03-27 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
CN109462996A
(zh)
|
2016-03-17 |
2019-03-12 |
西达-赛奈医疗中心 |
通过rnaset2诊断炎性肠病的方法
|
CN108883195A
(zh)
|
2016-03-24 |
2018-11-23 |
拜耳制药股份公司 |
具有酶促可裂解基团的细胞毒性活性物质的前药
|
KR102558066B1
(ko)
|
2016-03-28 |
2023-07-25 |
인사이트 코포레이션 |
Tam 억제제로서 피롤로트리아진 화합물
|
AU2017241776B2
(en)
|
2016-03-29 |
2024-06-20 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
CN109476699B
(zh)
|
2016-06-02 |
2021-10-12 |
艾伯维公司 |
糖皮质激素受体激动剂及其免疫偶联物
|
CA3027445A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
CA3029977A1
(en)
*
|
2016-07-06 |
2018-01-11 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
US20180024132A1
(en)
|
2016-07-07 |
2018-01-25 |
Berg Llc |
Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
|
EP3487522A4
(en)
|
2016-07-19 |
2020-04-01 |
Teva Pharmaceuticals Australia Pty Ltd |
ANTI-CD47 COMBINATION THERAPY
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
CN106279414A
(zh)
*
|
2016-08-31 |
2017-01-04 |
天津医科大学总医院 |
人源性抗胰淀素抗体及其制备方法
|
CA3032251A1
(en)
|
2016-09-01 |
2018-03-08 |
Forschungsverbund Berlin E.V. |
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
|
WO2018041740A1
(en)
|
2016-09-01 |
2018-03-08 |
Bayer Pharma Aktiengesellschaft |
Non-covalent display system using fimgt/dsf
|
US11453726B2
(en)
|
2016-09-15 |
2022-09-27 |
Quadrucept Bio Limited |
Multimers, tetramers and octamers
|
US20190248920A1
(en)
|
2016-09-23 |
2019-08-15 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
MA46366A
(fr)
|
2016-09-30 |
2019-08-07 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
AU2017346488A1
(en)
|
2016-10-19 |
2019-05-30 |
Humabs Biomed Sa |
Anti-O1 antibodies and uses thereof
|
KR20190082815A
(ko)
|
2016-10-26 |
2019-07-10 |
세다르스-신나이 메디칼 센터 |
중화 항-tl1a 단일 클론 항체
|
US11208474B2
(en)
|
2016-11-16 |
2021-12-28 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL23 specific antibody
|
BR112019010349A2
(pt)
|
2016-11-23 |
2019-10-08 |
Bioverativ Therapeutics Inc |
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
KR20190097128A
(ko)
|
2016-12-16 |
2019-08-20 |
메르크 파텐트 게엠베하 |
루푸스 신염의 중증도 및 진행을 모니터링하기 위한 소변에서 검출된 갈렉틴 3 결합 단백질의 사용 방법
|
EP3558387B1
(de)
|
2016-12-21 |
2021-10-20 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
KR102556826B1
(ko)
|
2016-12-21 |
2023-07-18 |
바이엘 파마 악티엔게젤샤프트 |
효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
|
CA3047491A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018141029A1
(en)
|
2017-02-06 |
2018-08-09 |
Meat & Livestock Australia Limited |
Immunostimulating compositions and uses therefore
|
WO2018178936A1
(en)
|
2017-03-30 |
2018-10-04 |
Duke University |
Radiolabeled biomolecules and their use
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
GB201706477D0
(en)
|
2017-04-24 |
2017-06-07 |
Bicycle Therapeutics Ltd |
Modification of polypeptides
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
EP3401328A1
(en)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
One step antibody humanization by golden gate based germline framework region shuffling
|
EP3403649A1
(en)
|
2017-05-16 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Inhibitors and antagonists of gpr84 for the treatment of endometriosis
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
EP3406253A1
(en)
|
2017-05-24 |
2018-11-28 |
Bayer Aktiengesellschaft |
Inhibitors and antagonists of human pycr1
|
SG11201911527QA
(en)
|
2017-06-05 |
2020-01-30 |
Numab Therapeutics AG |
Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
PT3658184T
(pt)
|
2017-07-27 |
2023-11-29 |
Alexion Pharma Inc |
Formulações de anticorpo anti-c5 de elevada concentração
|
WO2019025811A1
(en)
|
2017-08-04 |
2019-02-07 |
Bicycletx Limited |
SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
EP3459968A1
(en)
*
|
2017-09-20 |
2019-03-27 |
Numab Innovation AG |
Novel stable antibody variable domain framework combinations
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
ES2939461T3
(es)
|
2017-11-29 |
2023-04-24 |
Csl Ltd |
Método para tratar o prevenir la lesión por isquemia-reperfusión
|
JP7344206B2
(ja)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
二重特異性抗体製品のための連続製造プロセス
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
US20210087267A1
(en)
|
2017-12-20 |
2021-03-25 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
US20210251899A1
(en)
|
2018-01-25 |
2021-08-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
WO2019149637A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
WO2019160976A1
(en)
|
2018-02-14 |
2019-08-22 |
Viela Bio, Inc. |
Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
|
KR20200139153A
(ko)
|
2018-02-27 |
2020-12-11 |
인사이트 코포레이션 |
A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
|
AU2019232624A1
(en)
|
2018-03-05 |
2020-09-10 |
Janssen Biotech, Inc. |
Methods of treating Crohn's disease with anti-IL23 specific antibody
|
SG11202008186RA
(en)
|
2018-03-07 |
2020-09-29 |
Forschungsverbund Berlin Ev |
Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
|
SG11202008390SA
(en)
|
2018-03-14 |
2020-09-29 |
Surface Oncology Inc |
Antibodies that bind cd39 and uses thereof
|
EP3768317A4
(en)
|
2018-03-22 |
2021-12-22 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND USES THEREOF
|
ES2960925T3
(es)
|
2018-03-23 |
2024-03-07 |
Univ Bruxelles |
Moléculas agonistas de la señalización de WNT
|
RS64431B1
(sr)
|
2018-03-26 |
2023-09-29 |
Glycanostics S R O |
Sredstva i postupci za glikoprofilisanje proteina
|
WO2019190877A1
(en)
|
2018-03-26 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
High throughput method for measuring the protease activity of complement c3 convertase
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US11471506B2
(en)
|
2018-04-23 |
2022-10-18 |
Emory University |
VIP antagonists and uses in treating cancer
|
US20210070871A1
(en)
|
2018-04-25 |
2021-03-11 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
KR102115300B1
(ko)
*
|
2018-06-01 |
2020-05-26 |
재단법인 목암생명과학연구소 |
항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
|
EP3801613A1
(en)
|
2018-06-04 |
2021-04-14 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
EA202190059A1
(ru)
|
2018-06-18 |
2021-04-21 |
Байер Акциенгезельшафт |
Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
IL300821A
(en)
|
2018-07-05 |
2023-04-01 |
Incyte Corp |
Fused pyrazine derivatives as A2A/A2B inhibitors
|
MX2021000037A
(es)
|
2018-07-05 |
2021-03-25 |
Bayer Ag |
Nueva formulacion estable de alta concentracion para anticuerpos anti-fxia.
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
SG11202100710TA
(en)
|
2018-07-30 |
2021-02-25 |
Amgen Res Munich Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
CN112512581A
(zh)
|
2018-08-03 |
2021-03-16 |
安进研发(慕尼黑)股份有限公司 |
针对cldn18.2和cd3的抗体构建体
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833443A1
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigen binding agents that bind cd277 and uses thereof
|
LT3843757T
(lt)
|
2018-08-27 |
2024-07-10 |
Affimed Gmbh |
Kriokonservuotos nk ląstelės iš anksto pakrautos antikūno konstruktu
|
EP3849600A1
(en)
|
2018-09-12 |
2021-07-21 |
ACM Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
PT3883606T
(pt)
|
2018-09-24 |
2023-10-18 |
Janssen Biotech Inc |
Método seguro e eficaz de tratamento da colite ulcerosa com anticorpo anti il12/il23
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン,インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
WO2020104943A2
(en)
|
2018-11-20 |
2020-05-28 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il-23 specific antibody
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
US11447551B2
(en)
|
2018-12-28 |
2022-09-20 |
Sparx Bioscience Limited |
Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
|
JP7539897B2
(ja)
|
2019-01-16 |
2024-08-26 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
ヒトcd137に結合する抗体の製剤およびその使用
|
US20220128561A1
(en)
|
2019-01-17 |
2022-04-28 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
CN113365661A
(zh)
|
2019-01-31 |
2021-09-07 |
新加坡科技研究局 |
用于治疗或预防癌症的cnx/erp57抑制剂
|
CN113728107B
(zh)
|
2019-02-18 |
2022-06-24 |
Atb治疗公司 |
在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
|
US20200291107A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
US20200331996A1
(en)
|
2019-03-18 |
2020-10-22 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
US20220249458A1
(en)
|
2019-04-04 |
2022-08-11 |
Bayer Aktiengesellschaft |
Agonists Of Adiponectin
|
JP7285957B2
(ja)
|
2019-04-09 |
2023-06-02 |
ニューヨーク ソサイアティ フォー ザ リリーフ オブ ザ ラプチャード アンド クリップルド メインテイニング ザ ホスピタル フォー スペシャル サージェリー |
iRhom2のタンパク質バインダー
|
SG11202111824UA
(en)
|
2019-04-30 |
2021-11-29 |
Larimar Therapeutics Inc |
Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
JP2022537650A
(ja)
|
2019-06-13 |
2022-08-29 |
アムジエン・インコーポレーテツド |
生物製剤の製造における自動化された生物量に基づく灌流制御
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
KR20220044527A
(ko)
|
2019-08-01 |
2022-04-08 |
인사이트 코포레이션 |
Ido 억제제의 투여 요법
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
WO2021055329A1
(en)
|
2019-09-16 |
2021-03-25 |
Surface Oncology, Inc. |
Anti-cd39 antibody compositions and methods
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
JP2022550390A
(ja)
|
2019-09-30 |
2022-12-01 |
スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング |
iRhom2エピトープに結合するタンパク質バインダー
|
GB201914233D0
(en)
|
2019-10-02 |
2019-11-13 |
Bicyclerd Ltd |
Phage cyclisation assay
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
KR20220103721A
(ko)
|
2019-10-24 |
2022-07-22 |
프로메테우스 바이오사이언시즈, 인크. |
Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
US20230034584A1
(en)
|
2019-12-04 |
2023-02-02 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
EP4077363A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Il-37 fusion proteins and uses thereof
|
EP4081554A1
(en)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
AU2020417813A1
(en)
|
2020-01-03 |
2022-08-25 |
Incyte Corporation |
Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors
|
CA3160204A1
(en)
|
2020-01-06 |
2021-07-15 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|
KR20220167276A
(ko)
|
2020-03-10 |
2022-12-20 |
매사추세츠 인스티튜트 오브 테크놀로지 |
NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
CN116390947A
(zh)
|
2020-08-17 |
2023-07-04 |
Atb治疗公司 |
包含核糖体毒素或RNAse的重组免疫毒素
|
WO2022047359A1
(en)
|
2020-08-31 |
2022-03-03 |
Berg Llc |
Protein biomarkers for pancreatic cancer
|
MX2023002940A
(es)
|
2020-09-11 |
2023-04-11 |
Medimmune Ltd |
Moleculas de union a b7-h4 terapeuticas.
|
JP2023542301A
(ja)
|
2020-09-12 |
2023-10-06 |
メディミューン リミテッド |
抗b7h4抗体薬物コンジュゲート療法のためのスコア化方法
|
JP7454106B2
(ja)
|
2020-09-15 |
2024-03-21 |
バイエル・アクチエンゲゼルシヤフト |
新規な抗a2ap抗体およびその使用
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
CA3198064A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
TW202233679A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究(慕尼黑)公司 |
選擇性地與cldn6和cd3結合的多肽構建體
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
EP4251138A1
(en)
|
2020-11-30 |
2023-10-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
KR20230157940A
(ko)
|
2020-12-29 |
2023-11-17 |
인사이트 코포레이션 |
A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
|
MX2023008261A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
TW202245844A
(zh)
|
2021-01-13 |
2022-12-01 |
紀念斯隆凱特琳癌症中心 |
抗dll3抗體-藥物結合物
|
WO2022180172A1
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
WO2022184594A1
(en)
|
2021-03-01 |
2022-09-09 |
Scirhom Gmbh |
Humanized antibodies against irhom2
|
US20220298236A1
(en)
|
2021-03-12 |
2022-09-22 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
KR20230158526A
(ko)
|
2021-03-18 |
2023-11-20 |
메디뮨 리미티드 |
Ccr9에 결합하는 치료용 결합 분자
|
CA3213771A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
EP4314047A1
(en)
|
2021-03-30 |
2024-02-07 |
Bayer Aktiengesellschaft |
Anti-sema3a antibodies and uses thereof
|
US20230059578A1
(en)
|
2021-04-06 |
2023-02-23 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
CA3214819A1
(en)
|
2021-04-06 |
2022-10-13 |
Guisong WANG |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
EP4320443A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
CA3214755A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Natalie CASTELLANA |
Method for antibody identification from protein mixtures
|
AU2022258552A1
(en)
|
2021-04-12 |
2023-10-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
WO2022223783A1
(en)
|
2021-04-23 |
2022-10-27 |
Forschungsverbund Berlin E.V. |
Thiol-conjugation with unsaturated phosphorus(v) compounds
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
EP4367138A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
EP4376958A1
(en)
|
2021-07-30 |
2024-06-05 |
Affimed GmbH |
Duplexbodies
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
KR20240051162A
(ko)
|
2021-09-02 |
2024-04-19 |
도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 |
부작용이 감소된 항-cecam6 항체
|
US20230190805A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Methods of identifying metastatic lesions in a patient and treating thereof
|
CN118475608A
(zh)
|
2021-10-29 |
2024-08-09 |
詹森生物科技公司 |
用抗il23特异性抗体治疗克罗恩病的方法
|
AU2022381918A1
(en)
|
2021-11-03 |
2024-06-13 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023078968A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023078224A1
(zh)
|
2021-11-03 |
2023-05-11 |
同润生物医药(上海)有限公司 |
新型抗l1cam抗体
|
US20230192886A1
(en)
|
2021-11-08 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
WO2023083919A1
(en)
|
2021-11-09 |
2023-05-19 |
Tubulis Gmbh |
Conjugates comprising a phosphorus (v) and a camptothecin moiety
|
IL312675A
(en)
|
2021-11-09 |
2024-07-01 |
Tubulis Gmbh |
Conjugates involving phosphorus (V) and a drug component
|
AU2022388887A1
(en)
|
2021-11-15 |
2024-07-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
IL313021A
(en)
|
2021-11-23 |
2024-07-01 |
Janssen Biotech Inc |
A method for treating ulcerative colitis with a specific anti-IL23 antibody
|
TW202334231A
(zh)
|
2021-12-22 |
2023-09-01 |
德商莫菲西斯公司 |
抗cd19抗體療法的治療範例
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023156634A1
(en)
|
2022-02-17 |
2023-08-24 |
Atb Therapeutics |
Recombinant immunotoxin comprising a ribosome inactivating protein
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
US20230357851A1
(en)
|
2022-04-06 |
2023-11-09 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring frataxin-replacement therapy
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023240201A1
(en)
|
2022-06-08 |
2023-12-14 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
WO2024033362A1
(en)
|
2022-08-08 |
2024-02-15 |
Atb Therapeutics |
Humanized antibodies against cd79b
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024072893A1
(en)
|
2022-09-28 |
2024-04-04 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
WO2024074762A1
(en)
|
2022-10-03 |
2024-04-11 |
Turun Yliopisto |
Ultrastable antibody fragments with a novel disuldide bridge
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
WO2024105206A1
(en)
|
2022-11-17 |
2024-05-23 |
Vincerx Pharma Gmbh |
Antibody-drug-conjugates cleavable in a tumor microenvironment
|
WO2024105205A1
(en)
|
2022-11-17 |
2024-05-23 |
Bayer Aktiengesellschaft |
Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2024161038A1
(en)
|
2023-02-03 |
2024-08-08 |
Immusmol Sas |
Method of predicting success of a cancer therapy
|